Anti-SMYD3 Antibody (R2L71)

Catalog No.

RHK20902

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

FCM: 1:20-1:100, IF: 1:50-1:200, IHC: 1:100-1:200, IP: 1:20-1:50, WB: 1:1000-1:2000

Target

Zinc finger MYND domain-containing protein 1, SET and MYND domain-containing protein 3, SMYD3, ZMYND1, Histone-lysine N-methyltransferase SMYD3, ZNFN3A1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9H7B4

Applications

FCM, IF, IHC, IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R2L71

Oncogenic activation of SMYD3-SHCBP1 promotes breast cancer development and is coupled with resistance to immune therapy., PMID:40157910

Matrix stiffness-dependent PD-L2 deficiency improves SMYD3/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC., PMID:39159723

A SMYD3/ITGB6/TGFβ1 Positive Feedback Loop Promotes the Invasion and Adhesion of Ovarian Cancer Spheroids., PMID:34621667

ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma., PMID:30646949

A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer., PMID:26695438

Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways., PMID:21531130

Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas., PMID:20725992

Document Download

Anti-SMYD3 Antibody (R2L71).pdf